Table 2.

Small molecule TRPC3, C6, C7 antagonists.

Namea	Structure	Target	Concentration or IC50	Reference
GSK2332255B (GSK255B)		TRPC3 TRPC6	IC50, 5 nM IC50, 4 nM	Seo et al., 2014
GSK2833503A (GSK503A)		TRPC3 TRPC6	IC50, 21 nM IC50, 3 nM	Seo et al., 2014
BI 749327		TRPC3 TRPC6 TRPC7	IC50, 1,100 nM IC50, 13 nM IC50, 550 nM	Lin et al., 2019
Anilino-thiazoles		TRPC3 TRPC6	100 nM 16 nM	Washburn et al., 2013
SAR7334		TRPC3 TRPC6 TRPC7	IC50, 282 nM IC50, 7.9 nM IC50, 226 nM	Maier, et al., 2015
BTDM		TRPC3 TRPC6	IC50, 11 nM IC50, 10 nM	Tang, et al., 2018
Larixyl acetate		TRPC3 TRPC6 TRPC7	12 fold > C6 IC50, ~0.1 μM 5 fold > C6	Urban et al., 2016
SH045		TRPC3 TRPC6 TRPC7	13 fold > C6 IC50, ~5.8 nM 3.5 fold > C6	Hafner et al., 2018
Pyrazolopyrimidines 14a		TRPC6	IC50, 1 μM	Ding et al., 2018
Pyr10		TRPC3 TRPC6	IC50, 0.72 μM IC50 ≥ 10 μM	Schleifer et al., 2012
Pyr3		TRPC3	IC50, 0.7 μM	Kiyonaka et al., 2009; Koenig et al., 2013
DS88790512		TRPC6	IC50, 11 nM	Motoyama, et al., 2018
Salvianolic acid B		TRPC3 TRPC6	27.8 μM	Chen et al., 2017b
Sodium tanshinone IIA sulfonate (STS)		Attenuated TRPC6, C1 upregulation	12.5 μM	Wang et al., 2013a Jiang et al., 2016a.
Ribemansides A		TRPC6	IC50, 24.5 μM	Zhou et al., 2018
Ribemansides B		TRPC6	IC50, 25.6 μM	Zhou et al., 2018
Topotecan (TPT),		Suppressed expression of TRPC6	1–10 nM	Jiang et al., 2018
FK506		Attenuated TRPC6 upregulation	6.2 μM	Ma et al., 2015
Rosiglitazone (RSG)		Reduced TRPC6, C1 activation	10 μM	Wei et al., 2017
Sildenafil		Suppressed TRPC6 expression	300 nM	Lu et al., 2010
(‑)‑Oleocanthal (OLCT)		Suppressed TRPC6 expression	10–20 μM	Diez-Bello, et al., 2019
Pioglitazone		Suppressed TRPC6 expression	12 mg/kg body weight (in vivo), 1 μM (in vitro)	Sonneveld et al., 2017

^aCompounds with selectivity information and likelihood of direct interaction with the channel are highlighted in bold letters and shaded rows.